RESUMO
The present study was performed to investigate the protective effects of granulocyte macrophage-colony stimulating factor (GM-CSF) against ulcerative mucositis in hamster buccal pouch. GM-CSF was topically administered to the buccal pouches of hamsters with two different doses of 5 and 20 microg/ml. The treatment of GM-CSF led to rapid healing effects in gross and histopathological findings. It decreased expression of pro-inflammatory cytokine mRNA levels in the mucosal tissue of buccal pouches. Also GM-CSF-treated animals showed high numbers of Ki-67 positive cells in basal cell layer. These results suggest that GM-CSF provided excellent healing effects to ulcerative mucositis in the buccal pouch of hamster.
Assuntos
Antiulcerosos/uso terapêutico , Fluoruracila/toxicidade , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Mucosa Bucal/efeitos dos fármacos , Úlceras Orais/tratamento farmacológico , Estomatite/tratamento farmacológico , Administração Tópica , Animais , Biomarcadores/metabolismo , Cricetinae , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Masculino , Mesocricetus , Mucosa Bucal/metabolismo , Mucosa Bucal/patologia , Úlceras Orais/induzido quimicamente , Úlceras Orais/patologia , Proteínas Recombinantes , Estomatite/induzido quimicamente , Estomatite/patologiaRESUMO
Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.
